• AMZN
• AZN
• CARLb
• GOOGL
• MSFT
• OREP

Morning Bid: Focus swings back to rate moves, company earnings

• AAF
• AZN
• BEZG
• CL
• ENT
• GBP/USD
• GC
• ICAG
• LCO
• MRON
• UK100

U.K. stocks higher at close of trade; Investing.com United Kingdom 100 up 0.04%

U.K. stocks increased after the close, led by Industrial Transportation and Banking sectors, with notable performances from Melrose and International Airlines Group.

• AZN
• DX
• GC
• HEXAb
• HMb
• LCO
• OMXS30
• USD/SEK

Sweden stocks higher at close of trade; OMX Stockholm 30 up 0.80%

Sweden's OMX Stockholm 30 rose 0.80%, with Hexagon AB leading gains, while AstraZeneca fell. Oil and gold prices also fluctuated, and currency values declined.

• AZN

AstraZeneca shares trade higher on UBS Upgrade

• AZN
• DIS
• MRNA
• MSTR
• PFE
• XBI

Investing.com's stocks of the week

Highlights significant movements in Disney, MicroStrategy, and vaccine stocks affecting investments this week, focusing on earnings, Bitcoin acquisition, and public health policy concerns.

• AZN
• GSK
• MRNA
• PFE
• XBI

Vaccine stocks drop as Trump picks RFK Jr for US health job

Vaccine stocks fell sharply after Donald Trump nominated Robert F. Kennedy Jr., a vaccine skeptic, as Secretary of HHS, raising concerns over future public health policies.

• AZN
• FTMC
• GSK
• LAND
• UK100
• VLX

FTSE 100 subdued as pharma stocks weigh

UK stock indexes struggled as AstraZeneca and GSK fell amidst an unexpected economic contraction, causing setbacks for growth plans despite some gains in mining and property sectors.

• AZN
• MRNA
• OVID
• PFE

Analysis-RFK Jr vow to purge FDA sets up collision with Big Pharma

Robert F. Kennedy Jr. plans to reform the FDA, but faces industry pushback due to his controversial views on vaccines and potential staffing changes under Trump's administration.

• AZN

AstraZeneca raises 2024 outlook on strong Q3

AstraZeneca raised its 2024 sales and profit forecasts due to strong Q3 results, bolstered by key product performances and a promising drug pipeline outlook.

• AZN

AstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investments

AstraZeneca raises its 2024 sales forecast following strong third-quarter results, and announces $2 billion investment in U.S. operations amid concerns over its Chinese business.